Fibroblast Growth Factor-23 (FGF23)

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

The Fibroblast Growth Factor-23 (FGF23) gene resides on human chromosome 12p13 (mouse chromosome 6). It comprises three coding exons and contains an open reading frame of 251 residues. FGF23 has overlapping function with PTH to reduce renal Pi reabsorption, but it has the opposite effects on 1,25(OH)2D. FGF23 is measured in the circulation via several assays. One extensively used assay is a "C-terminal" FGF23 ELISA with both the capture and detection antibodies binding the C-terminal to the FGF23 176RXXR179/S cleavage site. This assay thus recognizes full-length FGF23 as well as C-terminal proteolytic fragments. This chapter discusses the disorders associated with both increased and reduced FGF23 bioactivity. Some of these disorders include autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), autosomal recessive hypophosphatemic rickets types 1 and 2, familial tumoral calcinosis, and chronic kidney disease (CKD).

Original languageEnglish (US)
Title of host publicationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition
PublisherWiley Blackwell
Pages188-194
Number of pages7
ISBN (Electronic)9781118453926
ISBN (Print)9781118453889
DOIs
StatePublished - Jul 19 2013

Fingerprint

Assays
Chromosomes
Familial Hypophosphatemic Rickets
Hypophosphatemic Rickets
Calcinosis
Chromosomes, Human, Pair 6
Human Chromosomes
Bioactivity
fibroblast growth factor 23
Chronic Renal Insufficiency
Open Reading Frames
Tumors
Exons
Genes
Enzyme-Linked Immunosorbent Assay
Antibodies
Autosomal Dominant Hypophosphatemic Rickets
Renal Reabsorption
Oncogenic osteomalacia

Keywords

  • Autosomal dominant hypophosphatemic rickets (ADHR)
  • Autosomal recessive hypophosphatemic rickets
  • Chronic kidney disease (CKD)
  • Familial tumoral calcinosis
  • Fibroblast growth factor-23 (FGF23)
  • Serum assays
  • Tumor-induced osteomalacia (TIO)
  • X-linked hypophosphatemic rickets (XLH)

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

White, K., & Econs, M. (2013). Fibroblast Growth Factor-23 (FGF23). In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition (pp. 188-194). Wiley Blackwell. https://doi.org/10.1002/9781118453926.ch24

Fibroblast Growth Factor-23 (FGF23). / White, Kenneth; Econs, Michael.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley Blackwell, 2013. p. 188-194.

Research output: Chapter in Book/Report/Conference proceedingChapter

White, K & Econs, M 2013, Fibroblast Growth Factor-23 (FGF23). in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley Blackwell, pp. 188-194. https://doi.org/10.1002/9781118453926.ch24
White K, Econs M. Fibroblast Growth Factor-23 (FGF23). In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley Blackwell. 2013. p. 188-194 https://doi.org/10.1002/9781118453926.ch24
White, Kenneth ; Econs, Michael. / Fibroblast Growth Factor-23 (FGF23). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley Blackwell, 2013. pp. 188-194
@inbook{05c98fb557054e8684aeee4a6e14f30f,
title = "Fibroblast Growth Factor-23 (FGF23)",
abstract = "The Fibroblast Growth Factor-23 (FGF23) gene resides on human chromosome 12p13 (mouse chromosome 6). It comprises three coding exons and contains an open reading frame of 251 residues. FGF23 has overlapping function with PTH to reduce renal Pi reabsorption, but it has the opposite effects on 1,25(OH)2D. FGF23 is measured in the circulation via several assays. One extensively used assay is a {"}C-terminal{"} FGF23 ELISA with both the capture and detection antibodies binding the C-terminal to the FGF23 176RXXR179/S cleavage site. This assay thus recognizes full-length FGF23 as well as C-terminal proteolytic fragments. This chapter discusses the disorders associated with both increased and reduced FGF23 bioactivity. Some of these disorders include autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), autosomal recessive hypophosphatemic rickets types 1 and 2, familial tumoral calcinosis, and chronic kidney disease (CKD).",
keywords = "Autosomal dominant hypophosphatemic rickets (ADHR), Autosomal recessive hypophosphatemic rickets, Chronic kidney disease (CKD), Familial tumoral calcinosis, Fibroblast growth factor-23 (FGF23), Serum assays, Tumor-induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH)",
author = "Kenneth White and Michael Econs",
year = "2013",
month = "7",
day = "19",
doi = "10.1002/9781118453926.ch24",
language = "English (US)",
isbn = "9781118453889",
pages = "188--194",
booktitle = "Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Fibroblast Growth Factor-23 (FGF23)

AU - White, Kenneth

AU - Econs, Michael

PY - 2013/7/19

Y1 - 2013/7/19

N2 - The Fibroblast Growth Factor-23 (FGF23) gene resides on human chromosome 12p13 (mouse chromosome 6). It comprises three coding exons and contains an open reading frame of 251 residues. FGF23 has overlapping function with PTH to reduce renal Pi reabsorption, but it has the opposite effects on 1,25(OH)2D. FGF23 is measured in the circulation via several assays. One extensively used assay is a "C-terminal" FGF23 ELISA with both the capture and detection antibodies binding the C-terminal to the FGF23 176RXXR179/S cleavage site. This assay thus recognizes full-length FGF23 as well as C-terminal proteolytic fragments. This chapter discusses the disorders associated with both increased and reduced FGF23 bioactivity. Some of these disorders include autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), autosomal recessive hypophosphatemic rickets types 1 and 2, familial tumoral calcinosis, and chronic kidney disease (CKD).

AB - The Fibroblast Growth Factor-23 (FGF23) gene resides on human chromosome 12p13 (mouse chromosome 6). It comprises three coding exons and contains an open reading frame of 251 residues. FGF23 has overlapping function with PTH to reduce renal Pi reabsorption, but it has the opposite effects on 1,25(OH)2D. FGF23 is measured in the circulation via several assays. One extensively used assay is a "C-terminal" FGF23 ELISA with both the capture and detection antibodies binding the C-terminal to the FGF23 176RXXR179/S cleavage site. This assay thus recognizes full-length FGF23 as well as C-terminal proteolytic fragments. This chapter discusses the disorders associated with both increased and reduced FGF23 bioactivity. Some of these disorders include autosomal dominant hypophosphatemic rickets (ADHR), tumor-induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), autosomal recessive hypophosphatemic rickets types 1 and 2, familial tumoral calcinosis, and chronic kidney disease (CKD).

KW - Autosomal dominant hypophosphatemic rickets (ADHR)

KW - Autosomal recessive hypophosphatemic rickets

KW - Chronic kidney disease (CKD)

KW - Familial tumoral calcinosis

KW - Fibroblast growth factor-23 (FGF23)

KW - Serum assays

KW - Tumor-induced osteomalacia (TIO)

KW - X-linked hypophosphatemic rickets (XLH)

UR - http://www.scopus.com/inward/record.url?scp=85009874217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009874217&partnerID=8YFLogxK

U2 - 10.1002/9781118453926.ch24

DO - 10.1002/9781118453926.ch24

M3 - Chapter

AN - SCOPUS:85009874217

SN - 9781118453889

SP - 188

EP - 194

BT - Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition

PB - Wiley Blackwell

ER -